Cargando…

The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling

We generated afatinib resistant clones of H1975 lung cancer cells by transient exposure of established tumors to the drug and collected the re-grown tumors. Afatinib resistant H1975 clones did not exhibit any additional mutations in proto-oncogenes when compared to control clones. Afatinib resistant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Booth, Laurence, Roberts, Jane L., Tavallai, Mehrad, Webb, Timothy, Leon, Daniel, Chen, Jesse, McGuire, William P., Poklepovic, Andrew, Dent, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991406/ https://www.ncbi.nlm.nih.gov/pubmed/26934000 http://dx.doi.org/10.18632/oncotarget.7746

Ejemplares similares

[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling
por: Booth, Laurence, et al.
Publicado: (2016)

Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS
por: Tavallai, Mehrad, et al.
Publicado: (2016)

Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2016)

Rationally Repurposing Ruxolitinib (Jakafi(®)) as a Solid Tumor Therapeutic
por: Tavallai, Mehrad, et al.
Publicado: (2016)

Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy
por: Cruickshanks, Nichola, et al.
Publicado: (2013)

OSU‐03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood–Brain Barrier: Implications for Anti‐Cancer Therapies
por: Booth, Laurence, et al.
Publicado: (2015)

The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met(+) Hepatocellular Carcinoma
por: Steinway, Steven N., et al.
Publicado: (2015)

Nexavar/Stivarga and Viagra Interact to Kill Tumor Cells
por: Tavallai, Mehrad, et al.
Publicado: (2015)

Enhanced Prediction of Src Homology 2 (SH2) Domain Binding Potentials Using a Fluorescence Polarization-derived c-Met, c-Kit, ErbB, and Androgen Receptor Interactome
por: Leung, Kin K., et al.
Publicado: (2014)

CDCP1 promotes compensatory renal growth by integrating Src and Met signaling
por: Kajiwara, Kentaro, et al.
Publicado: (2021)

Blocking c-MET/ERBB1 Axis Prevents Brain Metastasis in ERBB2+ Breast Cancer
por: Gautam, Shailendra K., et al.
Publicado: (2020)

Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations: afatinib in ERBB+ lung squamous cell carcinoma
por: Jian, Hong, et al.
Publicado: (2019)

Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells
por: Vengoji, Raghupathy, et al.
Publicado: (2019)

Lidocaine suppresses the malignant behavior of gastric cancer cells via the c-Met/c-Src pathway
por: Zeng, Wei, et al.
Publicado: (2021)

Aggregation of lipid rafts activates c-met and c-Src in non-small cell lung cancer cells
por: Zeng, Juan, et al.
Publicado: (2018)

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration
por: Booth, Laurence, et al.
Publicado: (2017)

Second-Line Treatment of NSCLC—The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms
por: Köhler, Jens
Publicado: (2017)

A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer
por: Modjtahedi, Helmout, et al.
Publicado: (2014)

A new solvate of afatinib, a specific inhibitor of the ErbB family of tyrosine kinases
por: Zeller, Matthias, et al.
Publicado: (2017)

Reconstitution of Mammary Gland Development In Vitro: Requirement of c-met and c-erbB2 Signaling for Branching and Alveolar Morphogenesis
por: Niemann, Catherin, et al.
Publicado: (1998)

MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells
por: Ebert, Karolin, et al.
Publicado: (2019)

Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma
por: Chun, Hyung-Wook, et al.
Publicado: (2019)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: A case report
por: Alshami, Jad, et al.
Publicado: (2015)

c-Src Recruitment is Involved in c-MET-Mediated Malignant Behaviour of NT2D1 Non-Seminoma Cells
por: Leonetti, Erica, et al.
Publicado: (2019)

Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies
por: Dent, Paul, et al.
Publicado: (2019)

An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis
por: Smith, Harvey W., et al.
Publicado: (2019)

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib
por: Booth, Laurence, et al.
Publicado: (2017)

Progranulin A Promotes Compensatory Hepatocyte Proliferation via HGF/c-Met Signaling after Partial Hepatectomy in Zebrafish
por: Chiang, Keng-Yu, et al.
Publicado: (2021)

Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties
por: Castoldi, R., et al.
Publicado: (2012)

Memorandum: recommendation of the Physics III Committee metting of 2 July, 1975
por: Lock, William Owen
Publicado: (1975)

c-src structure in human cancers with elevated pp60c-src activity.
por: Wang, P., et al.
Publicado: (1991)

Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB.
por: Aasland, R., et al.
Publicado: (1988)

Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients
por: Liu, Zhefeng, et al.
Publicado: (2018)

Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma
por: Mao, Xinfang, et al.
Publicado: (2016)

Matrine increases the inhibitory effects of afatinib on H1975 cells via the IL-6/JAK1/STAT3 signaling pathway
por: Chen, Shui-Fang, et al.
Publicado: (2017)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
por: Booth, Laurence, et al.
Publicado: (2019)

PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]
por: Booth, Laurence, et al.
Publicado: (2017)

Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells
por: Roberts, Jane L., et al.
Publicado: (2021)

Kinase inhibitors: look beyond the label on the bottle
por: Dent, Paul, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_75ftggbrs9qqclubgdhttsrk4p